LUCIDITY phase 3 topline data presented at CTAD for HMTM – the only oral anti-Tau therapy in late-stage development
– Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities – Topline results for the Phase 3 study, LUCIDITY, were shared at the Clinical Trials in Alzheimer’s Disease (CTAD) conference on Wednesday, 30th November 2022, in San Francisco – For people with early […]
